XML 36 R25.htm IDEA: XBRL DOCUMENT v3.19.1
Liquidity (Details) - USD ($)
 3 Months Ended 4 Months Ended 10 Months Ended
Apr. 25, 2019
Apr. 24, 2019
Sep. 21, 2018
Aug. 28, 2018
Jul. 25, 2018
Jun. 01, 2018
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Mar. 31, 2019
May 24, 2018
May 23, 2018
Liquidity [Line Items]                        
Net loss             $ 3,150,000 $ 4,409,000        
Accumulated deficit             (417,533,000)   $ (414,383,000) $ (417,533,000)    
Net cash used in operating activities             $ (3,270,000) (4,119,000)        
Substantial doubt about going concern, description             These factors raise substantial doubt about the Company’s ability to continue as a going concern.          
Cash and cash equivalents             $ 3,872,000   5,261,000 3,872,000    
Minimum cash/cash equivalents covenant             2,000,000     2,000,000    
Proceeds from sale of common stock, net             1,919,000 (150,000)        
Common stock issued (in shares)         6,723              
Number of shares callable by warrants (in shares)                     2,300,000 23,400,000
Proceeds from issuance warrants         $ 5,700,000              
Common stock issued, value             $ 1,873,000 $ 27,000        
Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member]                        
Liquidity [Line Items]                        
Cash proceeds from sale of subsidiary   $ 3,400,000                    
Subsequent Event [Member] | Cytori Ltd. and Cell Therapy Assets [Member] | Amendment to Loan and Security Agreement [Member]                        
Liquidity [Line Items]                        
Payments for principal, interest and fees   $ 1,700,000                    
Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member]                        
Liquidity [Line Items]                        
Cash proceeds from sale of subsidiary $ 2,500,000                      
Subsequent Event [Member] | Cytori Therapeutics, K.K. and Cell Therapy Assets used in Japan [Member] | Amendment to Loan and Security Agreement [Member]                        
Liquidity [Line Items]                        
Payments for principal, interest and fees $ 1,400,000                      
Nasdaq Stock Market LLC [Member]                        
Liquidity [Line Items]                        
Number of consecutive business days no longer able to meet the required closing bid price of common stock       30 days                
Minimum bid price of common stock required for Nasdaq listing rule       $ 1.00                
Grace period provided with minimum bid price for Nasdaq listing rule       180 days                
Grace date for minimum bid price requirement for Nasdaq listing       Feb. 25, 2019                
Common stock minimum bid price required to regain compliance       $ 1.00                
Number of consecutive business days required to regain compliance       10 days                
Date to regain compliance after meeting continued listing requirement       Aug. 26, 2019                
Additional grace period provided with minimum bid price to regain compliance       180 days                
Description of compliance with minimum bid price requirement             We were granted an additional compliance period of 180 calendar days, or until August 26, 2019, in which to regain compliance after meeting the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and providing notice to Nasdaq staff of our intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary.          
Series C Convertible Preferred Stock [Member]                        
Liquidity [Line Items]                        
Number of convertible shares converted into common stock (in shares)         8,400,000              
Number of shares callable by warrants (in shares)         7,059,150              
Common Stock [Member]                        
Liquidity [Line Items]                        
Common stock issued (in shares)         6,723   6,992,736 10,069        
Number of shares callable by warrants (in shares)         1              
Warrant exercise price (in dollars per share)         $ 0.7986              
Common stock issued, value             $ 7,000          
Common Stock [Member] | Series C Convertible Preferred Stock [Member]                        
Liquidity [Line Items]                        
Number of convertible shares converted into common stock (in shares)             82,645          
Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                        
Liquidity [Line Items]                        
Proceeds from sale of common stock, net                   $ 3,800,000    
Common stock issued (in shares)                   11,000,000    
Common Stock [Member] | Lincoln Park [Member]                        
Liquidity [Line Items]                        
Proceeds from sale of common stock, net                 300,000      
Common stock issued (in shares)             0          
Common stock issued, value     $ 5,000,000           $ 600,000      
Period exercisable from the date of issuance     24 months                  
Minimum [Member]                        
Liquidity [Line Items]                        
Unrestricted cash and cash equivalents             $ 2,000,000     $ 2,000,000    
Maximum [Member] | Common Stock [Member] | B. Riley FBR [Member] | Sales Agreement [Member]                        
Liquidity [Line Items]                        
Proceeds from sale of common stock, net           $ 6,500,000